Amgen $AMGN and UCB's romosozumab reduced fractures in late-stage study in postmenopausal women with osteoporosis. A Phase 3 trial, FRAME evaluating AMGEN and UCB�s romosozumab (AMG 785) for reducing the incidence of new vertebral fractures in postmenopausal women with osteoporosis met its endpoint.